Treating gastritis that tests negative for H. pylori starts with identifying which of several possible causes is driving the inflammation, because the treatment changes dramatically depending on the answer. Unlike H. pylori gastritis, where a standard antibiotic regimen does the heavy lifting, H. pylori-negative gastritis is really an umbrella term covering autoimmune attack on the stomach lining, damage from medications, bile washing back into the stomach, allergic-type eosinophilic inflammation, and other less common triggers. Each has its own management strategy, and getting it right depends on a thorough workup that sometimes includes confirming H. pylori is genuinely absent rather than just hiding.
Confirming That H. Pylori Is Actually Gone
Before pursuing treatment for a supposedly H. pylori-negative gastritis, it is worth making sure the bacterium is not being missed. Proton pump inhibitors, the acid-suppressing drugs millions of people take daily, are a well-known cause of false-negative test results. A study of 530 patients found that PPI use significantly reduced the sensitivity of the rapid urease test, dropping it from about 92% down to roughly 74% for the standard one-hour reading.1PubMed Central. Evaluation of methods for H. pylori detection in PPI consumption using culture, rapid urease test and smear examination A separate study found that patients taking PPIs were far less likely to be diagnosed with H. pylori gastritis compared to those who had never used them, with detection rates dropping from 71% to about 34%.2PubMed Central. Influence of proton pump inhibitors on gastritis diagnosis and pathologic gastric changes The standard recommendation is to stop PPIs at least two weeks before testing.
If you have been on a PPI and received a negative result, retesting after a washout period is a reasonable step. The stool antigen test holds up somewhat better during PPI use than the breath test or biopsy-based rapid urease test, maintaining sensitivity around 89% even while patients continued their medication.3PubMed Central. Influence of proton pump inhibitor treatment on Helicobacter pylori stool antigen test For truly ambiguous cases, PCR-based methods targeting multiple genes specific to H. pylori offer the highest accuracy and can detect even very low bacterial counts that other tests miss.4PubMed Central. Diagnosis of Helicobacter pylori: what should be the gold standard? Only once you are confident the infection is truly absent does it make sense to pursue cause-specific treatment.
When Pain Medications Are the Problem
Nonsteroidal anti-inflammatory drugs like ibuprofen, naproxen, and aspirin are one of the most common causes of gastritis in people without H. pylori. These medications damage the stomach lining through a two-step process: they block the enzymes that produce protective mucus and simultaneously trigger abnormal stomach contractions that increase the lining’s permeability and invite inflammatory cells in.5PubMed Central. Pathogenesis of NSAID-induced gastric damage: importance of cyclooxygenase inhibition and gastric hypermotility The damage is not purely a matter of acid eating through unprotected tissue; it involves a cascade where loss of protective prostaglandins leads to physical churning of the stomach wall, which then opens the door to further injury.
The treatment is straightforward in principle: stop the offending drug if possible. When that is not an option, as with people who need daily aspirin for heart protection or ongoing anti-inflammatory therapy for arthritis, three clinical strategies are used. The first and most effective is adding a PPI, which reduces the acid component of the injury and is considered the standard co-prescription. The second is switching to a selective COX-2 inhibitor, which spares some of the protective prostaglandin production. The third, relevant when H. pylori is actually present alongside NSAID use, is eradication of the bacterium.6PubMed Central. Current approaches to prevent NSAID-induced gastropathy–COX selectivity and beyond For people who are truly H. pylori-negative and cannot discontinue their NSAID, a PPI taken consistently is the mainstay.
Autoimmune Gastritis
Autoimmune gastritis is a distinct condition where the immune system attacks the acid-producing parietal cells concentrated in the upper portion of the stomach. Over time this destroys the cells responsible for both acid secretion and the production of intrinsic factor, a protein needed to absorb vitamin B12. But the consequences extend beyond B12. Because stomach acid is also required to absorb non-heme iron from food, iron deficiency often shows up first, sometimes years before any sign of B12 trouble, and is particularly common in younger women.7PubMed Central. Autoimmune gastritis
There is no drug that stops the autoimmune process itself. Treatment centers on replacing what the damaged stomach can no longer absorb and monitoring for complications. Screening for both iron and vitamin B12 deficiency is considered essential in anyone diagnosed with autoimmune gastritis, and correcting those deficiencies is a core part of management.8PubMed. Iron and Vitamin B12 Deficiency in Patients with Autoimmune Gastritis and Helicobacter pylori Gastritis: Results from a Prospective Multicenter Study Iron is typically given orally if tolerated, though some patients with severely reduced acid production absorb oral iron poorly and need intravenous infusions. Vitamin B12 is often given by injection to bypass the gut entirely, though high-dose oral B12 can work for some people since a small percentage is absorbed passively without intrinsic factor.
Autoimmune gastritis also carries a risk of gastric neoplasia, though the picture is more nuanced than older textbooks suggested. The yearly incidence of gastric adenocarcinoma in autoimmune gastritis patients ranges from roughly 0.1% to 0.5%, with the cancer risk appearing to be driven largely by concurrent or past H. pylori infection rather than autoimmune gastritis alone.9QJM: An International Journal of Medicine. Beyond metaplasia: unraveling the complex pathogenesis of autoimmune atrophic gastritis and its implications for gastric cancer risk That said, a different type of growth, called a type I neuroendocrine tumor, is more closely tied to the autoimmune process itself, with cumulative rates as high as about 15% over five years. Endoscopic surveillance therefore remains standard practice. One observational study of 150 patients with autoimmune atrophic gastritis found adenocarcinoma in about 5% at their first evaluation, and two additional cancers developed during follow-up, reinforcing the case for periodic endoscopy.10PubMed Central. The incidence of neoplasia in patients with autoimmune metaplastic atrophic gastritis: a renewed call for surveillance
Bile Reflux Gastropathy
Bile reflux gastritis occurs when bile from the small intestine washes backward into the stomach, irritating the lining. This is especially common after certain stomach surgeries that alter the normal valve between the stomach and duodenum, but it can also happen in people with an intact stomach. The hallmark symptoms are burning upper abdominal pain, nausea, and sometimes vomiting of bile-tinged fluid, and they tend not to respond well to standard acid-suppressing medications because the irritant is bile, not acid.
Ursodeoxycholic acid, a naturally occurring bile acid that is far less irritating than the dominant bile acids in human bile, is the most studied medical treatment. An early placebo-controlled trial found that taking 1,000 mg per day led to a dramatic decrease in pain intensity and frequency and nearly eliminated nausea and vomiting in patients with post-surgical bile reflux gastritis.11PubMed. Ursodeoxycholic acid treatment of bile reflux gastritis More recently, a systematic review and meta-analysis confirmed that adding ursodeoxycholic acid to standard therapy significantly reduced the number of reflux episodes, shortened their duration, and improved overall symptoms compared to standard therapy alone.12PubMed Central. Clinical Efficacy of Ursodeoxycholic Acid in Bile Reflux Gastritis: A Systematic Review and Meta-Analysis It works by changing the composition of the bile that reaches the stomach, replacing toxic bile acids with a gentler one. Prokinetic drugs, which help move stomach contents forward and reduce the backward flow of bile, are sometimes added. In severe post-surgical cases that do not respond to medication, a surgical revision to divert bile away from the stomach may be necessary.
Eosinophilic Gastritis
Eosinophilic gastritis is an allergic-type condition where a particular white blood cell, the eosinophil, infiltrates the stomach wall in abnormal numbers. The diagnosis is made by biopsy, typically requiring more than 20 eosinophils per high-power field after ruling out infections, medications, and other causes of eosinophilia.13PubMed Central. Eosinophilic gastroenteritis: diagnosis and clinical perspectives Symptoms include abdominal pain, nausea, early fullness, and sometimes diarrhea if the inflammation extends into the small bowel.
Treatment follows two broad paths. Corticosteroids are the most reliable pharmacological option and work quickly. A systematic review of pediatric cases found that roughly 50% to 70% of patients achieved both clinical and histological improvement with either corticosteroids or dietary elimination.14PubMed Central. Helicobacter pylori-negative Chronic Gastritis in Children: A Systematic Review The dietary approach involves removing the most common trigger foods, typically dairy, eggs, wheat, soy, nuts, and seafood, then reintroducing them one at a time to identify the culprit. In one well-documented case, eliminating these six food groups plus rice led to a reduction in eosinophil counts from over 20 per high-power field down to just 2–3, and the patient was able to stop steroids entirely once dairy and eggs were identified as her triggers.15PubMed Central. Successful Food-Elimination Diet in an Adult with Eosinophilic Gastroenteritis
Beyond steroids and elimination diets, other options include leukotriene receptor antagonists, mast-cell stabilizers, antihistamines, and newer biologic agents targeting the immune pathways that drive eosinophil recruitment.13PubMed Central. Eosinophilic gastroenteritis: diagnosis and clinical perspectives These tend to be reserved for patients who cannot tolerate steroids or who relapse when steroids are tapered. The evidence base for biologics in gastric eosinophilic disease is still growing, though results from eosinophilic esophagitis trials have been encouraging enough to drive research further down the gastrointestinal tract.
Mucosal Protectants and Supplements
Regardless of the underlying cause, a damaged stomach lining needs help healing. A class of drugs called mucoprotective agents works by bolstering the stomach’s own defenses rather than simply suppressing acid. These agents promote mucosal regeneration, reduce inflammation, and counteract oxidative stress.16PubMed Central. Pharmacological Treatment of Gastritis: A Narrative Review with a Systematic Literature Search
Rebamipide, widely used in parts of Asia, is one of the better-studied options. In a multicenter randomized trial comparing rebamipide to sucralfate in patients with chronic erosive gastritis, rebamipide was more effective at reducing both symptoms and endoscopic inflammation scores over eight weeks. It also significantly boosted prostaglandin E2 levels in the stomach lining, a marker of mucosal defense. The effect held regardless of whether patients were also infected with H. pylori, which means it works just as well for H. pylori-negative gastritis.17PubMed. Anti-inflammatory effects of rebamipide according to Helicobacter pylori status in patients with chronic erosive gastritis Rebamipide is not available in many Western countries, however, which limits its practical use for a large portion of patients.
Zinc L-carnosine is a supplement that has attracted clinical interest for its cytoprotective and anti-inflammatory properties in the stomach. Case reports have documented improvement in both symptoms and the histological appearance of chronic atrophic gastritis after treatment with zinc L-carnosine, with some authors suggesting it could slow the progression toward more serious gastric changes.18PubMed Central. Improvement in Chronic Atrophic Gastritis After Treatment with Zinc L-Carnosine The evidence is still limited to small studies and case reports, so it is best viewed as a potential adjunct rather than a standalone treatment. Sucralfate, an older mucosal protectant that forms a physical barrier over damaged tissue, remains available and is sometimes used alongside acid suppression, though the rebamipide trial suggested it is the less potent option.
Lymphocytic Gastritis and Other Rare Subtypes
A few uncommon forms of H. pylori-negative gastritis deserve mention because they require specialized management. Lymphocytic gastritis is defined by an abnormal accumulation of immune cells in the surface lining of the stomach, specifically more than 25 lymphocytes per 100 epithelial cells on biopsy.19Seminars in Diagnostic Pathology. Pathology and differential diagnosis of chronic, noninfectious gastritis It frequently appears alongside celiac disease, especially in children, where it has been found in 10% to 45% of those with confirmed celiac disease.14PubMed Central. Helicobacter pylori-negative Chronic Gastritis in Children: A Systematic Review When celiac disease is the driver, adopting a strict gluten-free diet often improves the gastric inflammation as well. In cases without celiac disease, treatment is less well defined and response to standard therapies tends to be poor.
Collagenous gastritis is rarer still. It features a thick band of collagen beneath the surface epithelium and can cause chronic abdominal pain and anemia. Available data on treatment are sparse, and the existing case literature suggests a disappointing response to most conventional therapies. For these uncommon subtypes, management is often guided by expert opinion and trial-and-error rather than robust clinical trials.
The Functional Dyspepsia Overlap
Many people with ongoing stomach symptoms and negative H. pylori tests do not have clearly identifiable inflammation on biopsy either. When upper endoscopy and biopsies look essentially normal but symptoms persist, the diagnosis often lands on functional dyspepsia, a disorder where the stomach’s nerve signaling and motility are off without visible damage. This diagnosis overlaps substantially with mild gastritis, and in practice, the same patient can carry both labels depending on which physician they see and how aggressive the biopsy sampling is.
Treatment for functional dyspepsia is symptom-directed and depends on which pattern dominates. Patients whose main complaint is pain or burning tend to respond to acid suppression or neuromodulators such as low-dose tricyclic antidepressants. Those whose primary issues are early fullness and bloating often do better with prokinetic drugs that help the stomach empty. Regional prescribing patterns reflect this: Western gastroenterologists lean more heavily on neuromodulators because pain-dominant presentations are more common in those populations, while Asian practice tends to favor prokinetics for the fullness and bloating that predominate there.20PubMed Central. Insights Into Functional Dyspepsia and Gastroparesis – Western Versus Asian Perspectives The point is that when H. pylori-negative gastritis does not respond to standard acid suppression and mucosal protectants, re-evaluating whether the symptoms are actually driven by a motility or nerve-signaling problem can open up additional treatment avenues.
Stress-Related Mucosal Disease in Critical Illness
A very different form of H. pylori-negative gastritis occurs in critically ill patients. Stress-related mucosal disease is caused by reduced blood flow to the stomach lining during severe illness, major trauma, or prolonged mechanical ventilation. It ranges from superficial erosions to deep ulcers and can lead to significant bleeding. The underlying mechanism is mucosal ischemia rather than acid hypersecretion or immune attack.21Clinical Therapeutics. Stress-related mucosal disease: Risk factors and prophylactic therapy
Prevention is the focus here rather than treatment after the fact. ICU patients at high risk, particularly those on ventilators or with clotting disorders, routinely receive prophylactic acid suppression with PPIs or histamine-2 receptor blockers. This strategy reduces major bleeding events, though it has not been conclusively shown to improve overall survival. For the average outpatient reader, this category is unlikely to apply, but it is worth knowing that the “gastritis” seen in hospitalized patients after major surgery or trauma is a fundamentally different beast from the chronic conditions discussed above and resolves when the underlying critical illness improves.
Tracking Atrophic Changes Over Time
For anyone with atrophic gastritis, where the stomach lining has thinned and the acid-producing glands have been lost, monitoring matters beyond just treating symptoms. Blood tests measuring pepsinogens and gastrin-17 can serve as non-invasive markers of how advanced the atrophy is. A study evaluating these markers found that combining pepsinogen I, pepsinogen II, the ratio between them, and gastrin-17 could detect chronic atrophic gastritis with moderate accuracy, and the test performed somewhat better for more advanced stages of atrophy.22BMC Gastroenterol. The potential value of serum pepsinogen and gastrin-17 for the diagnosis of chronic atrophic gastritis at different stages of severity These blood tests are not a replacement for endoscopy with biopsies but can help gauge disease progression between scoping sessions and flag patients who need closer surveillance.
The gastric microbiome may also play a role that is only beginning to be understood. In healthy stomachs, a diverse mix of bacteria is present, while chronic gastritis of any type tends to shift the community toward less diverse, potentially pro-inflammatory compositions.23PubMed Central. The Influence of Gastric Microbiota and Probiotics in Helicobacter pylori Infection and Associated Diseases Whether probiotic interventions can meaningfully restore a healthier microbial balance in the stomach remains an open research question. Some clinicians already recommend probiotics as an adjunct, especially after antibiotic courses, but the evidence specific to H. pylori-negative gastritis is thin enough that it should not be treated as a proven therapy.